Cargando…
Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial
Maintenance immunosuppression with belatacept following kidney transplantation results in improved long-term graft function as compared with calcineurin inhibitors. However, broad application of belatacept has been limited, in part related to logistical barriers surrounding a monthly (q1m) infusion...
Autores principales: | Johnson, Aileen C., Karadkhele, Geeta M., Shenvi, Neeta, Easley, Kirk A., Larsen, Christian P., Badell, I. Raul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977481/ https://www.ncbi.nlm.nih.gov/pubmed/36875938 http://dx.doi.org/10.1097/TXD.0000000000001449 |
Ejemplares similares
-
Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021) -
Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019) -
Longitudinal Evaluation of Cytopenias in the Renal Transplant Population
por: Johnson, Aileen C., et al.
Publicado: (2022) -
Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023) -
Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms
por: de Graav, Gretchen N., et al.
Publicado: (2018)